HPLC manufacturing and service expansion
Eksigent Technologies has announced that it will be stepping up its manufacturing capabilities by 40%, as well as expanding the company?s servicing capabilities, to meet demand for its HPLC products.
Eksigent Technologies has announced that it will be stepping up its manufacturing capabilities by 40%, as well as expanding the company’s servicing capabilities, to meet demand for its HPLC products.
"The need for this increase in product build capability is being driven by higher than expected customer demand for both our cHiPLC-nanoflex for proteomics, introduced in February of this year, and our ExpressHT-Ultra HPLC system for ADME-Tox and DMPK studies, introduced last fall," said David Neyer, vice president and co-founder of the company, in a statement.
The cHiPLC-nanoflex system is a docking station for up to three microfluidic chips that contain nanoLC or trap columns. The ExpressHT-Ultra HPLC system provides small molecule analysis for LC–MS studies of pharmacokinetics and drug metabolism.
The company is also recruiting additional field service personnel to provide maintenance for the growing number of customer installations. The money for the extra staff, tools and equipment was approved by the company’s board of directors last month.
For more on the company visit www.eksigent.com
RAFA 2024 Highlights: Contemporary Food Contamination Analysis Using Chromatography
November 18th 2024A series of lectures focusing on emerging analytical techniques used to analyse food contamination took place on Wednesday 6 November 2024 at RAFA 2024 in Prague, Czech Republic. The session included new approaches for analysing per- and polyfluoroalkyl substances (PFAS), polychlorinated alkanes (PCAS), Mineral Oil Hydrocarbons (MOH), and short- and medium-chain chlorinated paraffins (SCCPs and MCCPs).
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.
